If you sell adhesion barriers, surgical membranes, or tissue allografts, every claims tool you've tried has told you your market doesn't exist. It exists. Medicare just files it where reps never look. This page shows you exactly where, with the real numbers.
Adhesion barriers (HCPCS C1765) and human connective-tissue allografts like acellular dermal matrix (C1762) are facility-billed device codes, packaged into the surgery's payment. They never appear in Medicare physician claims at any volume, so claims searches return nothing. The market is visible anyway: Sunshine Act payment rosters name every clinician your competitors pay, and the placement surgeries and adhesiolysis admissions show where the products get used. Prospect 811 packages that whole play into one page called a Target Pack.
I spent six years carrying a bag, so I know what you did before you landed here. You got your hands on some claims data, maybe a free CMS lookup, maybe an expensive platform, and you typed in your codes. C1762 for the allografts. C1765 for the barrier. And you got nothing. Not a small market. Not a "suppressed" market. Zero rows, in every year the files go back.
So you concluded what any reasonable person would: the data can't help you. And you went back to working referrals and cold doors while reps in claims-visible markets pull ranked target lists for every account they walk into.
Zero was never the size of your market. Zero is an artifact of how hospitals bill. Here's what's actually going on, and then the three lists that fix it.
C-codes are device codes on the hospital's claim, not the surgeon's. When a colorectal surgeon lays a barrier in after a colectomy, the barrier rides the facility bill, and Medicare pays for it inside the surgery's lump payment (status indicator N, if you want to look it up: packaged, no separate line, no separate dollar). The surgeon's claim, the one every physician-level dataset is built from, never mentions your product at all.
That's why the zero is bulletproof. No physician-claims search can see a C-code market. Not ours, not anyone's, at any price. There is no public CMS dataset that carries C-code utilization. If a tool promises to rank your C1765 buyers straight from claims, ask them very carefully where the numbers come from.
So instead of searching claims for a product that isn't there, you triangulate: three legs, all public data, all named. Here they are, with the actual numbers.
The Sunshine Act requires manufacturers to report every payment to a clinician: consulting, speaker fees, meals, royalties, research. No claim-count minimum, no suppression, full names. For a market that's invisible in claims, the competitor payment roster is the closest thing to a specialist directory that exists.
| Product (as filed) | Clinicians paid | Reported payments | Years |
|---|---|---|---|
| AlloDerm | 3,401 | $51.2M | 2019-2025 |
| Seprafilm | 1,541 | $222K | 2020-2025 |
| Cortiva Allograft Dermis | 941 | $2.8M | 2019-2025 |
| Adept | 598 | $168K | 2019-2025 |
| FlexHD Acellular Hydrated Dermis | 383 | $69K | 2019-2023 |
| DermACELL | 231 | $590K | 2019-2025 |
| Suspend | 43 | under $1K | 2019-2020 |
| Gynecare Interceed | 2 | $59K | 2019-2020 |
Source: CMS Open Payments (Sunshine Act) public files, 2019-2025, as filed by the manufacturers. Product names appear as reported; AlloDerm also appears under a second case-variant filing covering 57 more clinicians.
Two honesty notes, because in this market trust is the whole sale. A payment recipient is a clinician engaged with a competitor, not a confirmed user. It's still the warmest cold list you will ever hold in this space. And MiMedx reports its payments under generic product strings, so its birth-tissue line can't be rostered by product name; you pull those from its manufacturer payment page instead, which the app also has.
Read the table like intel, not just a list. Seprafilm's roster is 1,541 names on about $222K, an average of $144 a head, which reads as broad low-dollar engagement rather than consulting contracts. Gynecare Interceed stopped appearing after 2020. The rosters tell you who's engaged, how deeply, and with whom.
Medicare's physician files do show who performs the operations where barriers and grafts get placed. Four groups, each with its own honest label:
Lysis-of-adhesions codes 44005, 44180, 58660, and 58740 have 15, 77, 2, and 4 Medicare billers ever. This market is itself hidden: Medicare suppresses any provider billing a code 10 or fewer times a year, and all-years search mode is how you surface even these names. Every one of them deals with the exact problem your barrier prevents.
Colectomy and open hysterectomy (44140, 44145, 44160, 44204, 44205, 58150). The open codes are collapsing under the suppression line as surgery goes laparoscopic: 44140 has 170 billers ever, 3 in 2024. The lap codes carry today's visible volume, and that shift is itself a talking point in your bag.
Tissue-expander and implant reconstruction (19340, 19342, 19357, 19364) is the acellular dermal matrix call point. Most of it is commercially insured, so Medicare shows you the tail of the market: 19357 has 135 billers ever, 16 in 2024. Real names, honest caveat.
1,792 surgeons have billed pubovaginal sling code 57288. The fascia autograft-harvest codes they'd otherwise need, 20920 and 20922? Three billers and nine billers, ever. Slings get done, fascia doesn't get harvested. That gap is your allograft story, written in Medicare's own numbers.
Hospitals bill peritoneal adhesiolysis admissions under MS-DRGs 335, 336, and 337, and that data is public too: 15,061 discharges nationally in 2024. The app ranks every facility by adhesiolysis volume, in your state or across the country, with year-over-year trend and average Medicare payment per stay.
That's your account list. The buildings where adhesion disease shows up, whether or not any surgeon's claim ever names your product. Cross it with Leg 1 and you know which of a hospital's surgeons are already talking to your competitors before you ever walk in.
Inside Prospect 811 this triangulation ships as a Target Pack: Adhesion Barriers & Tissue Allografts. Open it, set your state or territory zips, and the three legs load as ranked, filterable lists: the payment rosters with dollars and per-clinician detail, the placement surgeons from live claims, and the facility accounts by DRG. Every row clicks through to a full profile with contact info, and everything feeds the built-in CRM, day routes, and Doug, the built-in AI assistant.
The standing caveats, on the page where you decide instead of buried in a footnote: this is traditional Medicare fee-for-service data, so commercially-insured volume (most breast recon, for instance) is undercounted. Payment rosters mean engagement, not usage. And Medicare hides any provider billing a code 10 or fewer times a year, which is the entire reason this pack exists.
Already a user? Jump straight to the pack.
Prospect 811 is $79 a month on your personal card, self-serve, cancel anytime, with a 14-day full refund. Open the pack, set your territory, and walk into your next call already knowing who's engaged with your competitors.
Start prospecting → Try the interactive demoBuilt on public CMS data. Not affiliated with or endorsed by CMS.